NEW YORK – Cel-Sci on Thursday said it will initiate a Phase III registrational trial of its immunotherapy Multikine (leukocyte interleukin injection) in newly diagnosed, locally advanced head and ...

Concordance of circulating tumor DNA and imaging surveillance in patients with urothelial carcinoma and renal cell carcinoma post-immunotherapy.

Meanwhile, Lilly and Innovent are running upwards of 20 studies as they play catch-up with other PD-1/PD-L1 drugs testing the drug in other indications, including kidney, liver, colorectal ...

During a live event, Alexander I. Spira, MD, PhD, and participants NGS testing practices and the rationale behind their ...

Predicting how cancer patients will respond to treatment remains a critical challenge. Immune checkpoint inhibitors (ICIs), a ...

It is the second drug in the PD-1/PD-L1 inhibitor class to be cleared in a subcutaneous injection form by the FDA after Roche's Tecentriq Hybreza (atezolizumab and hyaluronidase) – which got a ...

When PD-1 binds to PD-L1 or PD-L2 on tumor cells or other cells, T cell functions are subdued. Checkpoint blockade treatments interrupt this interaction. This allows stem–like T cells to proliferate ...

Infusion reactions that can sometimes be severe or life-threatening. Signs and symptoms of infusion reactions may include: ...

Colorectal cancer (CRC), which affects the colon or rectum, represents a significant public health challenge. It ranks as the ...

Recombinant human TSH (rhTSH) was developed to provide TSH stimulation without the requirement for THST withdrawal and the ...

After hours: February 20 at 6:14:15 PM EST ...